Early, Aggressive BP Lowering Tied to Better ICH Outcomes
Best results were found when treatment was administered within 3 hours of ICH symptoms, a pooled analysis of the four Intensive BP Reduction in Acute Cerebral Hemorrhage Trials (INTERACT1-4) showed.
While current guidelines set a target systolic BP of < 180 mm Hg within 1 hour of ICH symptom onset, the intensive treatment systolic target is < 140 Hg within 1 hour.
The new findings were published online on June 18 in The Lancet Neurology .
Timing Dependent?
In addition to evaluating the safety and efficacy of early intensive treatment for ICH, the investigators also aimed to assess the impact of treatment timing.
The INTERACT1-3 studies included 10,269 adults with acute ACH who presented within 6 hours of symptom onset and had a systolic BP of > 150 mm Hg.
INTERACT4 included 1043 patients with suspected acute stroke who had a systolic BP of ≥ 150 mm Hg within 2 hours of symptom onset. In addition, 1029 study participants had a hemorrhagic form of stroke.
All were randomly assigned to receive either intensive or guideline recommended BP-lowering treatment with locally available BP drugs within 1 hour.
Scores on the modified Rankin scale were used to determine functional recovery, the primary outcome measure for the pooled analysis.
Additionally, a CT substudy of nearly 3000 INTERACT participants was conducted to measure hematoma volume.
Mean systolic BP rates at 1 hour were significantly lower for the intensive treatment group compared to the guideline group (149.6 mm Hg vs 158.8 mm Hg, respectively; P < .0001).
Poor physical function, defined as a modified Rankin scale score of 3-6 at the end of follow-up, was significantly less likely after intensive BP lowering (odds ratio [OR], .85; P = .0001).
The intensive group also had reduced odds of neurologic deterioration within 7 days compared to the guideline group (OR, .76; P = .0002), as well as lower odds of any serious adverse event (OR, .84; P = .0003) or death (OR, .83; P = .002).
CT substudy results showed no significant effect on either relative or absolute hematoma growth in the first 24 hours from intensive vs guideline treatment.
However, when intensive BP lowering was initiated within 3 hours of symptom onset, functional recovery was improved and hematoma growth was reduced in almost 25% of the patients with serial CT scans, investigators noted.
Patients with mild-to-moderate severity, as measured by ICH scores, had even greater reductions in hematoma growth after early intensive BP-lowering treatment.
The new pooled analysis of all four INTERACT trials confirms findings from INTERACT4, presented at the 2024 European Stroke Organization Conference Annual Meeting and reported by Medscape Medical News .
'Time Is Brain'
In an accompanying editorial, David J. Werring, PhD, Department of Translational Neuroscience and Stroke, University College London Queen Square Institute of Neurology, London, noted that several previous studies showed no benefit of BP lowering in acute ischemic stroke, 'probably because acutely elevated blood pressure has a role in maintaining brain perfusion.'
However, the pathophysiology of stroke from ICH 'is different, with a major role for hematoma expansion within the first few hours, a therapeutic target which might be reduced' by intensive BP lowering, he wrote.
Still, Werring noted that possible benefits need to be weighed against possible risks; and he pointed out several study limitations, such as the low severity of ICH overall and the inclusion of INTERACT3 data, which may have introduced confounding from BP lowering being just one component of its treatment 'bundle,' alongside strict glucose control and anticoagulant reversal.
'Notwithstanding these important limitations, the data presented make a compelling case for ultra-early intensive blood pressure reduction as a potentially useful intervention to improve outcomes in people with acute ICH,' he wrote, adding that more research is needed.
'Meanwhile, the clear message from this meta-analysis is that earlier treatment is better, meaning that, once again, time is brain for patients with ICH,' Werring concluded.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Why is GDRX stock up 30% today? GoodRx strikes deal to sell Ozempic and Wegovy after Novo Nordisk's breakup with Hims
Share prices of GoodRx (NASDAQ: GDRX), the American healthcare company and telemedicine service, are currently soaring after the company announced that it will partner with Novo Nordisk to offer the lowest-ever out-of-pocket prices for Ozempic and Wegovy. Unsold completed new-build inventory is so high this $34B homebuilder is turning to investors 'Job hugging' is the newest career trend: Here's what it means—and why Gen Z is into it Spotify just redesigned the way you'll 'listen' to audiobooks According to a press release posted early on August 18, GoodRx has struck a deal with the pharmaceutical giant Novo Nordisk to sell its popular semaglutide medications, Ozempic and Wegovy, for just $499 per month to 'eligible self-paying customers.' GoodRx doesn't sell or dispense any drugs itself, but rather provides savings and coupons that can be applied in pharmacies. Its exclusive Ozempic and Wegovy offerings, available starting today, are the lowest out-of-pocket costs for the medications available on the market. The news comes just weeks after Novo Nordisk cut ties with the telehealth company Hims & Hers Health (NYSE: HIMS) over claims that Hims & Hers was selling 'knockoff' versions of Wegovy. It's a dispute that reflects a broader discussion around whether compounded semaglutide drugs—or non-FDA approved versions of brand-name medicines—are a violation of intellectual property laws. As of this writing, GoodRx's stock is up by more than 30% since market close. Here's what to know about Novo Nordisk's latest partnership and its ongoing legal battles against compounded GLP-1s. GoodRx's collaboration with Novo Nordisk In the last year alone, GoodRx reports that nearly 17 million people visited the site searching for information and savings on GLP-1 medications—a 22% increase from the previous year. 'Demand for GLP-1 medications is at an all-time high, but too many Americans still face barriers accessing them,' Wendy Barnes, GoodRX president and CEO, said in the press release. 'By partnering with Novo Nordisk, we're taking a significant step forward in making these innovative brand-name treatments more accessible for millions of people who need them.' In the past, a spokesperson told Fast Company, GoodRx has worked with both Novo Nordisk and its competitor Eli Lilly to offer commercially insured patients manufacturer savings cards on GLP-1s. The company has also offered savings on other types of weight loss/diabetes treatments, including Contrave, Dexcom G7, Lantus, and Qsymia. However, this is the first time that GoodRx has offered a cash price for a GLP-1. The $499 monthly self-pay cost will be available at more than 70,000 retail locations nationwide. Novo Nordisk's current legal battles over compounded GLP-1s So far, investors' response to GoodRx's new collaboration has been overwhelmingly positive. It stands in sharp contrast to Hims & Hers' recent breakup with Novo Nordisk, which caused the telehealth company's share prices to plummet in late June. Hims & Hers and Novo Nordisk parted ways over Hims & Hers' offering of compounded versions of Wegovy. Back in 2022, the Food and Drug Administration (FDA) declared a shortage of GLP-1 medications including Ozempic and Wegovy. Under this shortage notice, pharmacies were permitted to make compounded versions of the brand-name drugs using their active ingredient, semaglutide, and sell them at a lower cost. However, Hims & Hers has continued to sell its compounded version of Wegovy long after the FDA lifted the shortage back in February. Now, Novo Nordisk is arguing that these compounded drugs are both a violation of its intellectual property and potentially dangerous to patients, due to their lack of FDA approval. Early this month, Novo Nordisk announced 14 new lawsuits against small pharmacies, telehealth providers, and weight-loss clinics over compounded versions of Ozempic and Wegovy—bringing its total cases filed on the matter up to more than 130 in 40 states. Experts say that federal compounding laws are just vague enough to allow for various interpretations, meaning that Novo Nordisk's current legal challenges could shape the way courts interpret those boundaries in the future. In a statement to Yahoo Finance, Barnes offered a clear look into GoodRx's stance on compounded drugs: 'There's no question we could have tried to do something sooner from a compounded alternative pathway, but we have been very clear in our belief that it needed to be FDA-approved, lawfully approved. It just wasn't a pathway that we were going to support,' she said. This post originally appeared at to get the Fast Company newsletter:
Yahoo
an hour ago
- Yahoo
Scientists Say They've Found a Way to Reverse Aging in Human Skin Cells
Here's what you'll learn when you read this story: Researchers have found that serum from younger blood can be combined with bone marrow cells and injected into older skin cells, producing rejuvenating effects. This is known as heterochronic parabiosis—the transfer of the blood of a younger animal to an older one. Previous trials on rodents showed a reduction in signs of aging. Experiments have been in vitro so far, and there still needs to be more probing into the mechanisms of rejuvenation, but serum injections might someday be viable. Eternal youth has become a lucrative market, enabling the sale of bottled promises in the form of creams and serums that may or may not erase dark spots and smooth wrinkles. And the 'promises' are getting... creative. From phototherapy to vampire facials that claim to use your own blood as an anti-aging serum, futuristic treatments promise to rewind years of visible aging. But most so-called miracle procedures touted by glossy magazines have not been made truly viable. Vampire facials might do nothing more that drain your blood and your wallet, but a team of researchers led by scientists from Beiersdorf AG Research and Development in Hamburg, Germany, claim to have figured out how blood serum (all of the parts of your blood that don't involve clotting) could reverse the ravages of time—if combined with bone marrow cells, that is. Extracting serum from more youthful skin and combining it with bone marrow cells actually showed visible effects on skin cultures in vitro. The researchers concluded that there must be an interaction between blood and bone marrow cells that causes skin rejuvenation. Without the bone marrow cells, the serum had no effect (which explains why vampire facials are more hype than anything else). While this sounds almost as macabre as Countess Elizabeth Bathory allegedly bathing in the blood of virgins to restore her youth, no human sacrifices are required for this treatment. What the countess probably would have been looking for today is a process known as heterochronic parabiosis, which involves combining blood from two animals of different ages. Such experiments have been previously tested on older mice (which were given injections of blood and bone marrow cells from juveniles) and older rats (which were injected with the same type of youth cocktail from piglets). Both had positive outcomes, but this had never been tried on human skin—until now. 'As the population's life expectancy increases, it has become a major interest to understand the mechanisms of aging with the aim to promote healthy aging and extend the disease-free lifespan,' the researchers said in a study recently published in the journal Aging. 'The skin, as our largest organ, is a valuable tissue to investigate aging, as first signs of aging are mostly visible, and it reflects the overall human health.' To see if this approach could potentially work on humans, the Beiersdorf team injected human skin cell cultures with serum—one sample that did contain bone marrow cells and one that did not. And the bone marrow seemed to be the key. Bone marrow is so potent because of the types of cells it contains—various stem and progenitor cells, both of which can differentiate into various other cell types. Hematopoietic stem cells (HSCs), found in both blood and bone marrow, are immature cells that can develop into all types of blood cells and self-renew, making them a huge asset for regenerative medicine. Bone marrow stem cells are easily influenced by their surroundings, and depending on their environment, they secrete proteins that promote growth and help with tissue repair. But what is even more amazing is that they will migrate to skin and boost regeneration and repair while promoting homeostasis. Stem cells can lose some of their functionality and self-renewal abilities as skin ages, but when the skin cultures were exposed to blood serum and bone marrow cells from young donors, that re-introduction of young cells took years off the skin's biological age, increased the production of cells, and improved how the skin looked. The researchers think that this rejuvenation is caused by proteins from bone marrow cells responding to young blood—they discovered that bone marrow cells secreted 55 proteins related to age, and seven of these had rejuvenating abilities that improved the signs of skin aging. In upcoming studies, the researchers anticipate finding out whether young blood serum and bone marrow cells can possibly rejuvenate other organs, as well as how long the rejuvenating effects last. 'Future studies are needed to further validate our identified proteins in the context of systemic skin rejuvenation and aging [like] the prolongation of the culture time would be interesting to explore,' they said. Sorry, Countess Bathory. It turns out there is a valid scientific reason your blood baths were not the elixir of youth. You Might Also Like The Do's and Don'ts of Using Painter's Tape The Best Portable BBQ Grills for Cooking Anywhere Can a Smart Watch Prolong Your Life?
Yahoo
3 hours ago
- Yahoo
Type 2 diabetes patients set for major shake-up in care
People with type 2 diabetes in England are to get the biggest shake up of care in a decade which could see them offered treatments, including jabs that aid weight-loss, sooner. The health service should move from a one-size-fits-all approach of starting everyone on the same medication, to more personalised care that aims to prevent complications like heart failure and heart attacks, according to new draft guidance from the National Institute for Health and Care Excellence (Nice). This includes making newer type 2 diabetes drugs, known as SGLT-2 inhibitors, a first-line treatment option in a move that could eventually help save tens of thousands of lives. SGLT-2 inhibitors, which include canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin, are once-a-day tablets that reduce blood sugar levels by helping the kidneys remove glucose, which is passed from the body through urine. However, analysis by Nice found these drugs are under-prescribed. The new guidelines recommend patients who cannot tolerate metformin – the first-choice in type 2 diabetes medication – should start with an SGLT-2 inhibitor on its own. The decision comes after evidence suggested these drugs protect the heart and kidneys as well as controlling blood sugar, Nice said. It is estimated the change could save almost 22,000 lives once uptake reaches 90% of the population. Nice also suggests some groups of patients would also benefit from GLP-1 receptor agonists such as liraglutide or semaglutide sooner, rather than keeping them for the later stages of treatment. Semaglutide, sold under the brand name Ozempic, is licensed in the UK to treat type 2 diabetes, while its other brand – Wegovy – is also used by the NHS to help obese people lose weight. Professor Jonathan Benger, deputy chief executive and chief medical officer at Nice, said: 'This guidance means more people will be offered medicines where it is right to do so to reduce their future risk of ill health. 'This represents a significant evolution in how we approach type 2 diabetes treatment. 'We're moving beyond simply managing blood sugar to taking a holistic view of a person's health, particularly their cardiovascular and kidney health. 'The evidence shows that certain medicines can provide important cardiovascular benefits, and by recommending them as part of initial treatment, we could help prevent heart attacks, strokes and other serious complications before they occur. 'This is particularly important given that cardiovascular disease is the leading cause of death in people with type 2 diabetes.' Around 4.6 million people in the UK are living with diabetes, with nine in 10 of those having type 2. However, it is estimated that a further 1.3 million people may have undiagnosed type 2 diabetes. Nice analysed the records of 590,000 people and found SGLT-2 inhibitors are under-prescribed, particularly to women, older people, and black patients. Prof Benger added: 'The evidence from our analysis is clear. There are prescribing gaps that need to be addressed. 'The guideline update published today will help to increase equitable uptake of SGLT-2 inhibitors, which we know can prevent serious health complications.' Dr Waqaar Shah, chairman of the guideline committee, added: 'We know that SGLT-2 inhibitors are currently under-prescribed, and our health economics analysis shows that people living in the most deprived areas would particularly benefit from universal access to these treatments. 'These recommendations could help reduce health inequalities while providing better outcomes for everyone.' Elsewhere, the draft guidance suggests different treatments for diabetes patients with certain characteristics or health conditions. These include adults with cardiovascular disease, who should be offered a triple therapy including a GLP-1 receptor agonist. Meanwhile, adults diagnosed with type 2 diabetes before 40 should be offered dual therapy before a GLP-1 receptor agonist is considered, while patients with chronic kidney disease should have tailored recommendations based on their kidney function. A public consultation on the new Nice guidelines is open until October 2. Douglas Twenefour, head of clinical at Diabetes UK, said: 'This long-awaited announcement propels type 2 diabetes treatment into the 21st century. 'Boosting access to newer treatments will be transformative for people with type 2 diabetes, while ensuring the UK keeps pace with the global momentum in treating the condition. 'The majority of people with type 2 diabetes are not currently taking the most effective medication for them, putting them at risk of devastating diabetes-related complications. 'Diabetes is a leading cause of cardiovascular disease, and tailoring treatment based on individual risk could protect thousands against heart attacks and kidney disease. 'These guidelines could go a long way to easing the burden of living with this relentless condition, as well as helping to address inequities in type 2 diabetes treatments and outcomes.'
